Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia
- PMID: 22985658
- DOI: 10.1016/j.hrthm.2012.09.015
Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia
Abstract
Background: Coronary artery disease carries dual risk for atrial tachyarrhythmias and sudden cardiac death.
Objective: To examine whether low-dose ranolazine and/or dronedarone can protect against vulnerability to atrial fibrillation (AF) and ventricular tachyarrhythmias.
Methods: In chloralose-anesthetized, open-chest Yorkshire pigs (n = 15), the proximal segment of left circumflex (LCx) coronary artery was occluded to reduce flow by 75%. An electrode catheter was positioned on the left atrial appendage to measure AF threshold (AFT) before and during LCx coronary artery stenosis before and at 1 hour after dronedarone (0.5 mg/kg intravenous bolus over 5 minutes) and/or ranolazine administration (0.6 mg/kg intravenous bolus followed by 0.035 mg/kg/min).
Results: Before drug administration, LCx coronary artery stenosis lowered AFT from 25.2 ± 1.7 mA control (mean ± SEM) to 4.9 ± 1.0 mA baseline (P<.01). At the low doses, neither ranolazine (plasma concentration 2.4 ± 0.6 μM) nor dronedarone (plasma concentration 20.9 ± 3.5 nM) alone blunted the ischemia-induced reduction in AFT but were effective together (from 25.2 ± 1.7 mA control to 22.0 ± 3.0 mA during stenosis; P = not significant). AF duration (P<.03) and AF inducibility (P = .012) were reduced by ranolazine and dronedarone together but not by either drug alone. Concurrently, combined but not separate administration blunted the ischemia-induced surge in T-wave heterogeneity, a marker of risk for ventricular tachyarrhythmias (from 43.1 ± 11.1 μV control to 149.7 ± 15.1 μV during stenosis, P<.001, compared to 61.7 ± 13.7 μV control to 83.7 ± 15.8 μV during stenosis, P = not significant).
Conclusions: Combined administration of low doses of ranolazine and dronedarone exerts a potent antiarrhythmic action on ischemia-induced vulnerability to AF and ventricular tachyarrhythmias due to direct effects on myocardial electrical properties.
Copyright © 2013 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.Cardiovasc Ther. 2013 Dec;31(6):e63-71. doi: 10.1111/1755-5922.12035. Cardiovasc Ther. 2013. PMID: 23647657
-
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.J Am Coll Cardiol. 2010 Oct 5;56(15):1216-24. doi: 10.1016/j.jacc.2010.08.600. J Am Coll Cardiol. 2010. PMID: 20883928 Free PMC article.
-
Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model.Heart Rhythm. 2011 Apr;8(4):608-14. doi: 10.1016/j.hrthm.2010.11.029. Epub 2010 Nov 19. Heart Rhythm. 2011. PMID: 21094698
-
Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1751-64. doi: 10.1517/17425255.2014.974551. Epub 2014 Oct 28. Expert Opin Drug Metab Toxicol. 2014. PMID: 25349898 Review.
-
Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation.Ann Pharmacother. 2017 Mar;51(3):245-252. doi: 10.1177/1060028016673073. Epub 2016 Oct 6. Ann Pharmacother. 2017. PMID: 27758968 Review.
Cited by
-
Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation.Clin Med Insights Cardiol. 2013 Aug 11;7:127-40. doi: 10.4137/CMC.S8445. eCollection 2013. Clin Med Insights Cardiol. 2013. PMID: 23997577 Free PMC article.
-
Refractory atrial fibrillation effectively treated with ranolazine.Indian Heart J. 2014 Jan-Feb;66(1):115-8. doi: 10.1016/j.ihj.2013.12.024. Epub 2014 Jan 4. Indian Heart J. 2014. PMID: 24581108 Free PMC article. Review.
-
Protective effect of Suxiao jiuxin pill, a traditional Chinese medicine, against acute myocardial ischemia in dogs.BMC Complement Altern Med. 2015 Oct 19;15:373. doi: 10.1186/s12906-015-0908-9. BMC Complement Altern Med. 2015. PMID: 26481800 Free PMC article.
-
Marked exercise-induced T-wave heterogeneity in symptomatic diabetic patients with nonflow-limiting coronary artery stenosis.Ann Noninvasive Electrocardiol. 2018 Mar;23(2):e12503. doi: 10.1111/anec.12503. Epub 2017 Sep 26. Ann Noninvasive Electrocardiol. 2018. PMID: 28949056 Free PMC article. Clinical Trial.
-
Spectrum of clinical applications of interlead ECG heterogeneity assessment: From myocardial ischemia detection to sudden cardiac death risk stratification.Ann Noninvasive Electrocardiol. 2021 Nov;26(6):e12894. doi: 10.1111/anec.12894. Epub 2021 Sep 30. Ann Noninvasive Electrocardiol. 2021. PMID: 34592018 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical